News Releases

BALLINA, Co. Tipperary (Ireland) and BREA, Calif. (USA) – (March 15, 2018) — Long-term agreement expands Beckman Coulter customers’ access to high-quality QC products, supporting efficient...

Fully contained automation solution boosts laboratory productivity, workflow flexibility and testing quality BREA, Calif. — (Feb. 20 2018) — Beckman Coulter Diagnostics and NTE-SENER, the...

Beckman Coulter Diagnostics today announced the addition of 6-Acetylmorphine (6-AM) and Buprenorphine (BUP) assays to its broad menu of drugs-of-abuse tests that meet the demands of onsite testing...

Beckman Coulter Diagnostics announced FDA clearance of its automated Access AMH immunoassay for in vitro diagnostic (IVD) use in the U.S. This simple test aids healthcare providers in the...

A Beckman Coulter assumiu o compromisso de garantir aos clientes o recebimento de ensaios da mais alta qualidade, a tempo, para ajudar os profissionais de saúde e de laboratórios a oferecer...

Beckman Coulter ist fest entschlossen, seinen Kunden weiterhin erstklassige Assays zeitgerecht bereitzustellen, damit Ärzte und Labors ihre Patienten besser versorgen können. Zu diesem Zweck...

Beckman Coulter apuesta por que sus clientes puedan disponer a tiempo de análisis de la mayor calidad posible con el fin de contribuir a que los profesionales sanitarios y de laboratorio sean...

Beckman Coulter s'engage à garantir que ses clients bénéficient des tests de la plus haute qualité, dans les délais, afin d'aider les professionnels de santé et de laboratoire à fournir de...

Beckman Coulter is committed to ensuring customers receive the highest quality assays, on-time, to help healthcare and laboratory professionals provide better patient care. To further these goals,...

A study published in Prostate Cancer and Prostatic Diseases demonstrated that physicians elected to perform fewer biopsies when phi testing was included in their overall, routine, clinical assessment.